New knee osteoarthritis drug AD-211 enters phase 2 trial
NCT ID NCT07550231
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called AD-211 to find the best dose for easing knee pain from osteoarthritis. About 200 people with knee osteoarthritis will take part in this double-blind, placebo-controlled trial. The main goal is to measure pain reduction during activity over 24 hours.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS OF THE KNEES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.